Exp Clin Endocrinol Diabetes 2000; Vol. 108: 250-255
DOI: 10.1055/s-2000-8527
© Johann Ambrosius Barth

Pioglitazone in the treatment of type 2 diabetes mellitus: U.S. clinical experience

J. B. Buse
  • UNC Diabetes Care Center, Chapel Hill, NC, USA
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Zoom Image

Summary:

This paper reviews US clinical experience with pioglitazone, a recently released thiazolidinedione for the treatment of type 2 diabetes mellitus. In placebo controlled clinical studies, pioglitazone effectively improved glycaemic control, as evidenced by significant reductions in HbA1c and fasting blood glucose, for patients with type 2 diabetes. Pioglitazone also exhibited a positive impact on the abnormal lipid profile common in patients with type 2 diabetes (increased triglycerides and low HDL-cholesterol). Compared to placebo, pioglitazone, as monotherapy or in combination with sulphonylureas, metformin or insulin, significantly reduced serum triglyceride concentrations and increased HDL-cholesterol with no change in LDL or total cholesterol. Adverse event profiles were similar across the placebo and pioglitazone treated groups in the US clinical trial program. With respect to liver function tests, no differences from placebo were noted.